Most of CD5+ DLBCL cases (17 of 24, 70.8%) were MYC-positive compared with only two CD5- DLBCL (2 of 23, 8.7%) cases (P < 0.001). This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.